Clik here to view.
Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with...
FORT LAUDERDALE, Fla. & BEIJING Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of combination intratumoral immunotherapy announced today that the Company...
View ArticleClik here to view.
Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40...
BEIJING & FORT LAUDERDALE, Fla. Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today that...
View ArticleClik here to view.
Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in...
CRANBURY, N.J. & SHANGHAI Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first...
View ArticleClik here to view.
Urethral Stricture: BEES-HAUS Cell Therapy Approach Proven With Cell...
TOKYO Urethral stricture, blocking the passage of urine from the bladder in men, could be solved by BEES-HAUS cell therapy, a novel autologous buccal mucosal cell-based approach as reported by Dr....
View ArticleClik here to view.
Quizartinib Granted Priority Review in the U.S. for Patients with Newly...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of quizartinib in...
View ArticleClik here to view.
尿道狭窄：日本江户川医院的泌尿科医师证明，通过BEES-HAUS细胞治疗方法进行细胞移植有望预防复发
东京 (美国商业资讯)–男性尿道狭窄可阻断尿液从膀胱排出。著名泌尿科医生Akio Horiguchi博士报告称，BEES-HAUS细胞疗法有望解决这一问题。BEES-HAUS是一种基于自体颊粘膜细胞的新疗法。Akio Horiguchi博士已证实，该方法在日本的易于再现性，以及在尿道损伤和疤痕部位进行细胞移植是防止狭窄复发的关键步骤。研究尿道狭窄的Dmitriy...
View ArticleClik here to view.
Syncell Selects $50,000 Grant Opportunity Winners for Spatial Proteomics
TAIPEI, Taiwan & LOS ALTOS, Calif. Syncell, pioneering innovative tools to accelerate the world’s understanding of proteomics, today announced Melissa Wren, Ph.D., & Dmytro Morderer, Ph.D.,...
View ArticleClik here to view.
bioAffinity Technologies Announces Award of Therapeutic Patents in China,...
SAN ANTONIO, Texas bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced the People’s Republic of China awarded a Certificate of Patent to the Company’s wholly owned subsidiary OncoSelect®...
View ArticleClik here to view.
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory...
CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology...
View ArticleClik here to view.
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
Prestige Biopharma Group to Exhibit at CPhI Frankfurt 2022
SINGAPORE Prestige Biopharma group comprised of Prestige Biopharma Limited (950210: KRX) and Prestige Biologics Co., Ltd. (334970: KOSDAQ) is pleased to announce that it will be appearing at CPhI...
View ArticleClik here to view.
武田薬品工業：2022年度上期は力強い業績を達成、通期予想を上方修正
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TOKYO：4502/NYSE：TAK）は、本日、2022年度上期の業績を公表しましたのでお知らせします。当社は財務ベースおよびCoreベースの通期予想、フリー・キャッシュ・フローを上方修正し、Core財務指標のCERベース での通期マネジメントガイダンスを維持します。 当社代表取締役社長CEOのクリストフ・ウェバー（Christophe...
View ArticleClik here to view.
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2022 (period ended September 30, 2022), upgrading reported and core forecasts and free...
View ArticleClik here to view.
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate...
CAMBRIDGE, Mass. & SHANGHAI 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology...
View ArticleClik here to view.
エクセンシアが第34回EORTC-NCI-AACR年次シンポジウムでGTAEXS-617による患者層別化とバイオマーカーに関する新規データを発表
オーストリア・ウィーン & 英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq:...
View ArticleClik here to view.
Exscientia在第34届EORTC-NCI-AACR年度研讨会上展示GTAEXS-617的新型患者分层和生物标志物数据
奥地利维也纳和英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天公布了新的重要数据，旨在纳入更多有可能对其精确设计的CDK7抑制剂GTAEXS-617...
View ArticleClik here to view.
SYNLAB and Microba reinforce their combined expertise and expand strategic...
BRISBANE, Australia SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut...
View ArticleClik here to view.
武田发布强劲的2022财年上半年业绩并上调全年预期
日本大阪 (美国商业资讯)–武田(Takeda, TOKYO:4502/NYSE:TAK)今天公布了2022财年上半年（截至2022年9月30日的期间）的财务业绩，上调了本财年的报告和核心预测以及自由现金流展望，并重新确认了按恒定汇率(CER)计算的核心增长的管理层指引。 武田首席执行官Christophe Weber评论道：...
View ArticleClik here to view.
Clik here to view.
InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first adolescent patient...
View Article